

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**HUA MEDICINE**

**華領醫藥**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2552)**

## **APPOINTMENT OF EXECUTIVE DIRECTOR**

### **APPOINTMENT OF EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of Hua Medicine (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Dr. Yi ZHANG (“**Dr. Zhang**”) has been appointed as an executive Director with effect from January 1, 2024.

The biographical details of Dr. Zhang are set out below:

**Dr. Zhang** (張怡), aged 49, has been appointed as an executive Director with such appointment to take effect from January 1, 2024.

Dr. Zhang has been serving as the Senior Vice President of the Clinical Research and Development (“**R&D**”) division of the Company since April 2018. In August 2020, Dr. Zhang was promoted to the Senior Vice President of Pharma Development of the Company and the Company’s Chief Medical Officer – China. In November 2021, Dr. Zhang served as the Senior Vice President of Pharma Development of the Company and the Company’s Chief Medical Officer.

Prior to joining the Group in February 2013 as the Head of the Clinical R&D division of the Company, Dr. Zhang was the associate medical director of clinical science at Roche Product Development group (“**Roche**”), Asia Pacific region since early 2010. She served as a clinical scientist for innovative drug development in the areas of cardiovascular, metabolic and renal diseases. Prior to Roche, Dr. Zhang was as an Associate Professor and Physician worked at Shanghai Ruijin Hospital, affiliated to Shanghai Jiaotong University School of Medicine and as Physician worked at Shanghai Renji Hospital, affiliated to Shanghai Jiaotong University School of Medicine, from December 1999 to October 2010.

Dr. Zhang received her bachelor and master’s degrees in Clinical Medicine from Shanghai Jiaotong University School of Medicine in China in June 1997 and June 1999 respectively, and her PhD degree in Cardiology from Shanghai Jiaotong University School of Medicine in China in June 2004. As a Visiting Researcher, she studied at National Institutes of Health NIH/NHLBI Framingham Heart Study in the USA in 2009. Dr. Zhang was nominated as a “Shanghai Excelling Academic/Technical Leader” (上海市優秀學術／技術帶頭人) in 2015 and has authored 60 publications in journals such as Nature Genetics, Lancet Diabetes Endocrinol, Circulation: Cardiovascular Genetics, and has invented 3 China patents.

Dr. Zhang has entered into a service contract with the Company for an initial term of three years commencing from January 1, 2024, which may be terminated by not less than one month's notice in writing served by either Dr. Zhang or the Company. Dr. Zhang will hold office until the next annual general meeting of the Company at which she will be eligible for re-election. Thereafter, Dr. Zhang will be subject to retirement by rotation and re-election in accordance with the articles of association of the Company. Pursuant to the service contract, Dr. Zhang will not receive any additional director's fee or remuneration in her capacity as an executive Director as her remuneration was covered in her current employment agreement with the Company in her capacity as the Senior Vice President of Pharma Development of the Company and the Company's Chief Medical Officer based on the Company's current compensation levels and with reference to her qualification, experience and the prevailing market rate, but she is entitled to the reimbursement of all reasonable expenses properly incurred by her in connection with the performance of her duties as an executive Director of the Company.

Save as disclosed above, as at the date of this announcement, Dr. Zhang confirms that (i) she does not have any interest in any shares, underlying shares or debentures of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) she does not hold any other positions with the Company or any of its subsidiaries; (iii) she does not hold, and has not held in the last three years, any other directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas; (iv) she has no relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; (v) there is no other information in relation to the appointment of Dr. Zhang which is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"); and (vi) there are no other matters in relation to the appointment of Dr. Zhang that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its warm welcome to Dr. Zhang for joining the Company.

## **COMPLIANCE WITH RULE 13.92 OF THE LISTING RULES**

Reference is made to the announcement of the Company dated October 12, 2023 in relation to, among other things, the change of non-executive Director. Following the appointment of Dr. Zhang as an executive Director with effect from January 1, 2024, the Company has fully complied with the requirement set out in Rule 13.92 of the Listing Rules.

By Order of the Board

**Dr. Li Chen**

*Chief Executive Officer and Executive Director*

Hong Kong, December 29, 2023

*As of the date of this announcement, the Board comprises Dr. Li Chen, Mr. George Chien Cheng Lin and Dr. Yi Zhang as executive Directors; Mr. Robert Taylor Nelsen and Dr. Fangxin Li as non-executive Directors; and Mr. William Robert Keller, Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung as independent non-executive Directors.*